Drug Trial Radar · NCT02117817
Phase I BKM120/Abraxane in Solid Tumors, Expansion Phase Recurrent Endometrial or Ovarian Cancer
Last checked: Nov 20, 2026Latest source record: Jul 28, 2022 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Withdrawn
Enrollment
0
Actual
Start
Feb 2015
Primary completion
Feb 25, 2015
Study completion Feb 25, 2015
Sponsor
- Lead sponsor
- Rutgers, The State University of New JerseyAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Rutgers Cancer Institute of New Jersey; National Cancer Institute (NCI)
- First posted
- Apr 21, 2014
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of the first part of this study or the dose escalation portion of the study is to determine what dose of BKM120 and Abraxane is safe to give when the two drugs are used at the same time in patients who are diagnosed with a solid cancer. A solid cancer is a cancer that does not involve the blood, bone marrow or lymph nodes. Dose escalation determines the least toxic and most effect dose of this drug combination for treatment. Once this dose is established, it will be used for the dose expansion phase of the study where we will determine the effect of BKM120 and Abraxane in women diagnosed with a recurrent endometrial or ovarian cancer. We will see whether the combination of both drugs improves the response and survival of patients treated on the two drug regimen. Also we will try to find out whether there are changes in tumors that can help us determine what patients are more likely to respond to BKM120 and Abraxane.
Conditions
- Ovarian Cancer
- Endometrial Cancer
- Recurrent Ovarian Cancer
- Recurrent Endometrial Cancer
Interventions
BKM120Drug
NabpaclitaxelDrug
Given IV
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of adverse events graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events version 4.0Time frame: 2 years
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.